<p>根據斯堪的納維亞銀行（Skandinaviska Enskilda Banken AB publ）最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第三季度將其在 Summit Therapeutics PLC（NASDAQ:SMMT - 免費報告）中的持股增加了 409.2%。該公司在本季度額外購買了 271,912 股後，持有 338,363 股該公司的股票。斯堪的納維亞銀行在 Summit Therapeutics 的持股在最近一個季度末的價值為 6,991,000 美元。</p>
<p>獲取 <strong>Summit Therapeutics</strong> 的提醒：</p>
<ul>
<li>為什麼華爾街支持這三隻復甦股票</li>
</ul>
<p>其他機構投資者也對該公司的持股進行了調整。Crowley Wealth Management Inc.在第三季度將其在 Summit Therapeutics 的持股增加了 66.7%。Crowley Wealth Management Inc.現在擁有 1,500 股該公司的股票，價值 31,000 美元，此前在上個季度又購買了 600 股。SBI Securities Co. Ltd.在第二季度將其在 Summit Therapeutics 的持股增加了 34.1%。SBI Securities Co. Ltd.現在擁有 1,756 股該公司的股票，價值 37,000 美元，此前在此期間又購買了 447 股。PNC Financial Services Group Inc.在第二季度將其在 Summit Therapeutics 的持股增加了 325.5%。PNC Financial Services Group Inc.現在擁有 2,638 股該公司的股票，價值 56,000 美元，此前在上個季度又購買了 2,018 股。SG Americas Securities LLC 在第三季度獲得了 Summit Therapeutics 的新股份，價值 106,000 美元。最後，AlphaQuest LLC 在第二季度將其在 Summit Therapeutics 的持股增加了 131.7%。AlphaQuest LLC 現在擁有 5,891 股該公司的股票，價值 125,000 美元，此前在此期間又購買了 3,349 股。4.61% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Summit Therapeutics 股票表現</h2>
<p>NASDAQ:SMMT 週五開盤價為 15.87 美元。該公司的市值為 122.4 億美元，市盈率為-12.80，貝塔值為-1.44。該股票的 50 日移動平均價格為 16.67 美元，200 日移動平均價格為 19.50 美元。Summit Therapeutics PLC 的 52 周最低價為 13.83 美元，52 周最高價為 36.91 美元。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>MarketBeat 週報 – 11/4 - 11/8</li>
</ul>
<p>幾位股票研究分析師最近對該公司發佈了報告。Piper Sandler 在 1 月 14 日的研究報告中將 Summit Therapeutics 的目標價設定為 40.00 美元。Zacks Research 在 2 月 4 日的報告中將 Summit Therapeutics 的評級從 “持有” 下調至 “強烈賣出”。巴克萊在 12 月 17 日的報告中將 Summit Therapeutics 的評級從 “減持” 上調至 “持平”，並將其目標價從 16.00 美元提高至 18.00 美元。花旗在 1 月 30 日的研究報告中重申了對 Summit Therapeutics 的 “市場表現優於大盤” 評級。最後，HC Wainwright 在 2 月 2 日的研究報告中重申了 “買入” 評級，並對 Summit Therapeutics 的目標價設定為 40.00 美元。一位研究分析師對該股票給予了強烈買入評級，九位給予了買入評級，三位給予了持有評級，三位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 33.08 美元。</p>
<p><strong>查看我們對 Summit Therapeutics 的最新股票分析</strong></p>
<h2>關於 Summit Therapeutics</h2>
<p>（免費報告）</p>
<ul>
<li>Summit Therapeutics：他們的肺癌藥物是遊戲規則的改變者嗎？</li>
</ul>
<p>Summit Therapeutics plc 是一家臨牀階段的生物技術公司，致力於為嚴重和危及生命的疾病發現和開發精準醫療。該公司採用針對性的藥物設計方法，專注於與現有療法不同的新機制。</p>
<p>Summit 的主要資產，ridinilazole（前稱 SMT19969），正在開發用於治療艱難梭菌感染，並已獲得美國的快速通道和合格感染性疾病產品認證。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票比 Summit Therapeutics 更好</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>我的愛潑斯坦故事</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Summit Therapeutics 嗎？</h2>
<p>在考慮投資 Summit Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Summit Therapeutics 並不在名單上。</p>
<p>雖然 Summit Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做空 - Direxion

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

Summit治療

醫藥突破 ETF - ALPS

<p>斯堪的納維亞銀行（Skandinaviska Enskilda Banken AB publ）在第三季度將其在 Summit Therapeutics PLC 的持股增加了 409.2%，目前持有 338,363 股，價值為 699 萬美元。其他機構投資者也增加了他們的持股，Crowley Wealth Management 增加了 66.7%，PNC Financial Services 增加了 325.5%。Summit Therapeutics 的市值為 122.4 億美元，市盈率為-12.80。分析師的評級意見不一，普遍評級為 “適度買入”，平均目標價為 33.08 美元</p>

<p>Skandinaviska Enskilda Banken AB publ grew its position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 409.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 338,363 shares of the company's stock after buying an additional 271,912 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Summit Therapeutics were worth $6,991,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據斯堪的納維亞銀行（Skandinaviska Enskilda Banken AB publ）最近向證券交易委員會（SEC）提交的 13F 表格，該公司在 2023 年第三季度將其在 Summit Therapeutics PLC（NASDAQ:SMMT - 免費報告）中的持股增加了 409.2%。該公司在本季度額外購買了 271,912 股後，持有 338,363 股該公司的股票。斯堪的納維亞銀行在 Summit Therapeutics 的持股在最近一個季度末的價值為 6,991,000 美元。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Summit Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Why Wall Street Is Backing These 3 Comeback Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼華爾街支持這三隻復甦股票</li>
</ul>
</div><p>Other institutional investors have also made changes to their positions in the company. Crowley Wealth Management Inc. lifted its position in shares of Summit Therapeutics by 66.7% in the 3rd quarter. Crowley Wealth Management Inc. now owns 1,500 shares of the company's stock valued at $31,000 after acquiring an additional 600 shares in the last quarter. SBI Securities Co. Ltd. raised its stake in Summit Therapeutics by 34.1% during the 2nd quarter. SBI Securities Co. Ltd. now owns 1,756 shares of the company's stock valued at $37,000 after purchasing an additional 447 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Summit Therapeutics by 325.5% in the second quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock valued at $56,000 after purchasing an additional 2,018 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Summit Therapeutics in the third quarter worth $106,000. Finally, AlphaQuest LLC boosted its position in shares of Summit Therapeutics by 131.7% in the second quarter. AlphaQuest LLC now owns 5,891 shares of the company's stock worth $125,000 after buying an additional 3,349 shares during the period. 4.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者也對該公司的持股進行了調整。Crowley Wealth Management Inc.在第三季度將其在 Summit Therapeutics 的持股增加了 66.7%。Crowley Wealth Management Inc.現在擁有 1,500 股該公司的股票，價值 31,000 美元，此前在上個季度又購買了 600 股。SBI Securities Co. Ltd.在第二季度將其在 Summit Therapeutics 的持股增加了 34.1%。SBI Securities Co. Ltd.現在擁有 1,756 股該公司的股票，價值 37,000 美元，此前在此期間又購買了 447 股。PNC Financial Services Group Inc.在第二季度將其在 Summit Therapeutics 的持股增加了 325.5%。PNC Financial Services Group Inc.現在擁有 2,638 股該公司的股票，價值 56,000 美元，此前在上個季度又購買了 2,018 股。SG Americas Securities LLC 在第三季度獲得了 Summit Therapeutics 的新股份，價值 106,000 美元。最後，AlphaQuest LLC 在第二季度將其在 Summit Therapeutics 的持股增加了 131.7%。AlphaQuest LLC 現在擁有 5,891 股該公司的股票，價值 125,000 美元，此前在此期間又購買了 3,349 股。4.61% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Summit Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Summit Therapeutics 股票表現</h2>
</div><p>NASDAQ:SMMT opened at $15.87 on Friday. The company has a market capitalization of $12.24 billion, a P/E ratio of -12.80 and a beta of -1.44. The stock's 50 day moving average price is $16.67 and its 200 day moving average price is $19.50. Summit Therapeutics PLC has a 52 week low of $13.83 and a 52 week high of $36.91.</p>
<div class="lb-trans"><p>NASDAQ:SMMT 週五開盤價為 15.87 美元。該公司的市值為 122.4 億美元，市盈率為-12.80，貝塔值為-1.44。該股票的 50 日移動平均價格為 16.67 美元，200 日移動平均價格為 19.50 美元。Summit Therapeutics PLC 的 52 周最低價為 13.83 美元，52 周最高價為 36.91 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 11/4 - 11/8</li>
</ul>
</div><p>Several equities research analysts recently issued reports on the company. Piper Sandler set a $40.00 price objective on Summit Therapeutics in a research note on Wednesday, January 14th. Zacks Research downgraded Summit Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Wednesday, February 4th. Barclays upgraded shares of Summit Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and raised their price target for the stock from $16.00 to $18.00 in a report on Wednesday, December 17th. Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of Summit Therapeutics in a research report on Friday, January 30th. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $40.00 target price on shares of Summit Therapeutics in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $33.08.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發佈了報告。Piper Sandler 在 1 月 14 日的研究報告中將 Summit Therapeutics 的目標價設定為 40.00 美元。Zacks Research 在 2 月 4 日的報告中將 Summit Therapeutics 的評級從 “持有” 下調至 “強烈賣出”。巴克萊在 12 月 17 日的報告中將 Summit Therapeutics 的評級從 “減持” 上調至 “持平”，並將其目標價從 16.00 美元提高至 18.00 美元。花旗在 1 月 30 日的研究報告中重申了對 Summit Therapeutics 的 “市場表現優於大盤” 評級。最後，HC Wainwright 在 2 月 2 日的研究報告中重申了 “買入” 評級，並對 Summit Therapeutics 的目標價設定為 40.00 美元。一位研究分析師對該股票給予了強烈買入評級，九位給予了買入評級，三位給予了持有評級，三位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 33.08 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Summit Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Summit Therapeutics 的最新股票分析</strong></p>
</div><h2>About Summit Therapeutics</h2>
<div class="lb-trans"><h2>關於 Summit Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><ul>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics：他們的肺癌藥物是遊戲規則的改變者嗎？</li>
</ul>
</div><p>Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.</p>
<div class="lb-trans"><p>Summit Therapeutics plc 是一家臨牀階段的生物技術公司，致力於為嚴重和危及生命的疾病發現和開發精準醫療。該公司採用針對性的藥物設計方法，專注於與現有療法不同的新機制。</p>
</div><p>Summit's lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.</p>
<div class="lb-trans"><p>Summit 的主要資產，ridinilazole（前稱 SMT19969），正在開發用於治療艱難梭菌感染，並已獲得美國的快速通道和合格感染性疾病產品認證。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Summit Therapeutics</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>My Epstein Story</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Summit Therapeutics 更好</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>我的愛潑斯坦故事</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SMMT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Summit Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Summit Therapeutics 嗎？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Summit Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Summit Therapeutics 並不在名單上。</p>
</div><p>While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Summit Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Skandinaviska Enskilda Banken AB publ 持有 Summit 治療公司價值 699 萬美元的股份